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The Vulnerable Plaque “Hypothesis”
Promise, but Little Progress*
Steven E. Nissen, MD
Cleveland, OhioA PubMed search using the terms “vulnerable
plaque” or “high-risk” plaque yields 2,000 ref-
erences to journal articles published over the past
20 years. Indeed, few concepts in cardiovascular
medicine have achieved such intense scientific
interest over such a long duration. During this
20-year period, many diagnostic techniques de-
signed to “detect” vulnerable plaques have come
and gone. In each case, a flurry of promising
“findings” has been followed by a sobering reality
check. These include thermography, spectros-
copy, palpography, virtual histology, optical co-
herence tomography, and many more (1–5). A
large number of startup companies with “break-
through” approaches have come and gone, nearly
all leaving investors with empty pockets, but no
progress. What has gone wrong?
See page 473
It is time to face reality. Much of the contempo-
rary concept of vulnerable plaque is fundamentally
flawed or overly simplistic, and most approaches to
detection are poorly conceived. Many of the propo-
nents of vulnerable plaque detection have ap-
proached the problem with a naïve premise, namely,
that one merely needs to detect the “high-risk
plaque” and place a stent to preempt the “inevitable”
plaque rupture that might threaten the life of the
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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vascular Imaging or the American College of Cardiology.
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tax deduction.patient. The most ardent advocates have named this
approach “plaque sealing,” and some have actually
performed such interventions before large and rapt
audiences at major interventional “demonstration”
courses. However, this simplistic thinking immedi-
ately fails any reasonable scientific scrutiny. More
thoughtful studies have revealed a biological reality
that undermines the plausibility of the “let’s stent
the vulnerable plaque” approach.
First, to “seal” vulnerable plaques, you must find
them. However, most methods reported to date,
including the approach used by Gonzalo et al. (6) in
this issue of iJACC, seek to identify a “surrogate” for
the vulnerable plaque, specifically a lesion described
as a “thin cap fibroatheroma” (TCFA). Based upon
limited autopsy studies published by Virmani et al.
(7), nearly all authors in this field of research
assume that there is a direct 1-to-1 relationship
between a TCFA and a high-risk plaque. However,
in reality, there are few scientifically credible data
supporting such a relationship. Accordingly, it is
assumed, but not proven, that the presence of large
numbers of TFCAs represents a harbinger of future
vascular events.
After 20 years of research and countless clinical
studies, has any method of detection of high-risk
plaques successfully predicted which lesions are
most likely to rupture, resulting in an acute event?
Astonishingly, the answer is clearly “no.” There
exist no prospective clinical trials demonstrating
that presence of any specific plaque morphological
feature is associated with a worse prognosis for
patients. While it is true that autopsy studies
suggest that TCFAs are most often the culprit
lesions in acute coronary syndromes (ACS), it is
quite another matter to show that the presence of
this morphology prospectively predicts plaque be-
havior. In the absence of a proven relationship
between TCFAs and adverse outcomes, improved
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484ethods for detection of such lesions constitute
nly an academic exercise.
Let us, for the moment, accept the premise
hat the TCFA is truly the vulnerable lesion.
ow might we utilize this knowledge to improve
atient care and outcomes? First, we would need
o find and “map” all of the TCFAs. Because
cute cardiovascular events can involve any coro-
ary vessel, we would need to examine all of the
ajor epicardial arteries and their principal
ranches. These include not just the 3 major
oronaries, but also large obtuse marginal
ranches, diagonal branches, and the posterior
escending artery. In the case of the method
roposed by Gonzalo et al. (6), 2 separate imag-
ng modalities were employed. Such an approach
ould require subselectively placing a guidewire
n no less than 5 or 6 major vessels and carefully
nterrogating the length of these vessels, not
nce, but twice. All of this must be accomplished
ithout untoward events resulting from place-
ent of mechanical devices in these modestly
ized vessels.
Now let us, for the moment, assume that such
complete interrogation of the coronary circula-
ion is feasible. What are we likely to find? Many
houghtful investigators have shown that plaque
nstability is a distinctly multifocal phenomenon
8). We are not likely to find “the” vulnerable
laque, because, in fact, a multitude of such
igh-risk lesions are likely present. Available data
uggest that there may be dozens of lesions
resent, distributed throughout the coronary cir-
ulation. So, if we could find the vulnerable
laques, do we really think we could stent them
ll? If a handful of particularly high-risk lesions
ere detected and “sealed,” will the immediate
isks and late adverse consequence of coronary
ntervention (late stent thrombosis) actually ex-
eed any prospective benefits? The COURAGE
Clinical Outcomes Using Revascularization and
ggressive Drug Evaluation) trial suggests that
he risks of such a strategy may exceed any
enefits (9).
There is also the issue of the temporal relation-
hip between imaging procedures and vulnerability.
ny diagnostic method for vulnerable plaque de-
ection represents a snapshot in time. However, we
ave little information about the stability of plaque
orphologic measurements over time. If a plaque is
igh risk today, will it be high risk in 1 month, 3
onths, or a year from now? Intravascular ultra-ound studies of the regression and progression of 4therosclerosis suggest that the atheroma can
hange quite rapidly with medical therapy. If we
tent a vulnerable plaque, are we potentially inter-
ening with a lesion that is destined to become
uiescent in a few weeks or months? Conversely, if
e classify a location as stable, can we be certain
hat this site will not undergo acute conversion to a
ulnerable lesion a few weeks from now?
We must understand that atherosclerosis is a
ystemic disease, strongly associated with inflam-
ation and other widespread phenomena. In the
onths after an ACS, event rates remain elevated
ecause the systemic factors leading to the ACS are
till present. Stenting a few TCFAs will not change
he systemic inflammatory milieu. However, attack-
ng the underlying disease is feasible and has proven
ffective in many prospective trials. Statins, anti-
latelet agents, smoking cessation, and other med-
cal interventions lessen the likelihood of recurrence
fter an ACS. In contradistinction to the absence of
rogress in vulnerable plaque detection, medical
herapies have dramatically lowered event rates after
cute events during the past 20 years. These ther-
pies work because they do not approach the
vulnerable plaque” phenomenon as a local prob-
em; they attack the underlying systemic disease.
With this background in mind, the study by
onzalo et al. (6) can be placed in perspective. It
ffers some scientific insight into the distribution of
CFAs near coronary bifurcations, but does not
epresent a practical approach to identification of
ulnerable plaques. The approach also has impor-
ant weaknesses. The definitions for various tissue
ypes must be viewed as arbitrary, attempting to
efine a continuous phenomenon as a series of
iscrete variables. For example, a plaque with 9%
ecrotic core and cap thickness of 66 m would not
e classified as a TCFA, but a plaque with 11%
ecrotic core and 64 m cap thickness would be a
igh-risk lesion. Such arbitrary rules make little
iologic sense. In all likelihood, vulnerability is a
ontinuous variable, not a binary “yes” or “no”
henomenon. The 2 lesions may have little differ-
nce in their actual risk of plaque rupture.
Research, such as the current study by Gonzalo et
l. (6), should be encouraged, but we must accept
hat there is little likelihood of a near-term break-
hrough yielding important patient benefits. For
ow, such studies must be considered exploratory.
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